[en] OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained. RESULTS: In total, 115 patients were included (63 men and 52 women; mean age at diagnosis: 36.3 years). Mean baseline prolactin level was 2224 +/- 6839 ng/mL. No significant increase of tumor volume was observed during the follow-up. Of the 21 patients (18%) who presented asymptomatic hemorrhagic changes of the macroprolactinoma on MRI, 2 had a tumor increase (2 and 7 mm in the largest size). Both were treated by cabergoline (1 mg/week) with normal prolactin levels obtained for 6 and 24 months. For both patients, no further growth was observed on MRI during follow-up at the same dose of cabergoline. CONCLUSION: No significant increase of tumor size was observed in our patients with controlled prolactin levels on DA. MRI follow-up thus appears unnecessary in patients with biologically controlled macroprolactinomas.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Eroukhmanoff, J.
Tejedor, I.
Potorac, Iulia ; Université de Liège - ULiège > Doct. sc. médicales (Bologne)
Cuny, T.
BONNEVILLE, Jean-François ; Centre Hospitalier Universitaire de Liège - CHU > Service médical de radiodiagnostic
Dufour, H.
Weryha, G.
Beckers, Albert ; Université de Liège > Département des sciences cliniques > Endocrinologie
Touraine, P.
Brue, T.
Castinetti, F.
Language :
English
Title :
MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Ciccarelli A, Daly AF & Beckers A. The epidemiology of prolactinomas. Pituitary 2005 8 3-6. (doi:10.1007/s11102-005-5079-0)
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA & Wass JA. Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 273-288. (doi:10.1210/jc.2010-1692)
Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA & Pereira AM. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 2010 95 43-51. (doi:10.1210/jc.2009-1238)
Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF & Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology 2005 63 26-31. (doi:10.1111/j.1365-2265.2005.02293.x)
Iglesias P & Diez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM 2013 106 495-504. (doi:10.1093/qjmed/hcs240)
Vroonen L, Jaffrain-Rea M-L, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology 2012 167 651-662. (doi:10.1530/EJE-12-0236)
Karavitaki N, Thanabalasingham G, Shore HCA, Trifanescu R, Ansorge O, Meston N, Turner HE & Wass JA. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-defnition? A study of 226 patients with histologically verifed non-functioning pituitary macroadenoma. Clinical Endocrinology 2006 65 524-529. (doi:10.1111/j.1365-2265.2006.02627.x)
Colao A & Savastano S. Medical treatment of prolactinomas. Nature Reviews Endocrinology 2011 7 267-278. (doi:10.1038/nrendo.2011.37)
Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002 5 55-65. (doi:10.1023/A:1022375429083)
Pontikides N, Krassas GE, Nikopoulou E & Kaltsas T. Cabergoline as a frst-line treatment in newly diagnosed macroprolactinomas. Pituitary 2000 2 277-281. (doi:10.1023/A:1009913200542)
Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S & Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism 2004 89 1704-1711. (doi:10.1210/jc.2003-030979)
Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T & Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. Journal of Clinical Endocrinology and Metabolism 2008 93 4721-4727. (doi:10.1210/jc.2007-2758)
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A & Fahlbusch R. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273. (doi:10.1111/j.1365-2265.2006.02562.x)
Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A et al. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. Journal of Endocrinological Investigation 2016 39 1377-1382. (doi:10.1007/s40618-016-0483-z)
Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Journal of Clinical Endocrinology and Metabolism 2000 85 2247-2252. (doi:10.1210/jc.85.6.2247)
Lombardi M, Lupi I, Cosottini M, Rossi G, Manetti L, Raffaelli V, Sardella C, Martino E & Bogazzi F. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Hormone and Metabolic Research 2014 46 939-942. (doi:10.1055/s-0034-1389925)
Maiter D & Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. European Journal of Endocrinology 2014 170 R213-R227. (doi:10.1530/EJE-14-0013)
Carija R & Vucina D. Frequency of pituitary tumor apoplexy during treatment of prolactinomas with dopamine agonists: a systematic review. CNS and Neurological Disorders Drug Targets 2012 11 1012-1014. (doi:10.2174/1871527311211080011)
Möller-Goede DL, Brändle M, Landau K, Bernays RL & Schmid C. Pituitary apoplexy: re-evaluation of risk factors for bleeding into pituitary adenomas and impact on outcome. European Journal of Endocrinology 2011 164 37-43. (doi:10.1530/EJE-10-0651)
Zhu X, Wang Y, Zhao X, Jiang C, Zhang Q, Jiang W, Wang Y, Chen H, Shou X, Zhao Y et al. Incidence of pituitary apoplexy and its risk factors in Chinese people: a database study of patients with pituitary adenoma. PLoS ONE 2015 10 e0139088. (Disponible sur: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC4583273/).
Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Utz A & Wass JA. Acromegaly: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2014 99 3933-3951. (doi:10.1210/jc.2014-2700)
Mazziotti G & Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010 13 60-67. (doi:10.1007/s11102-009-0169-z)
Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I & Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 2012 7 e36411. (doi:10.1371/journal.pone.0036411)
Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B & Vantyghem MC. Ketoconazole in Cushing's disease: is it worth a try? Journal of Clinical Endocrinology and Metabolism 2014 99 1623-1630. (doi:10.1210/jc.2013-3628)
Bou Khalil R, Baudry C, Guignat L, Carrasco C, Guibourdenche J, Gaillard S, Bertagna X & Bertherat J. Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery. European Journal of Endocrinology 2011 165 729-737. (doi:10.1530/EJE-11-0424)